The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outpatient treatment-related toxicity after hospital discharge among patients receiving lifileucel for advanced melanoma.
 
James Smithy
Consulting or Advisory Role - Bristol-Myers Squibb; IO Biotech; Iovance Biotherapeutics
Research Funding - Daiichi Sankyo (Inst); IO Biotech (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Immatics
 
Hannah Kalvin
No Relationships to Disclose
 
Elizabeth Cathcart
No Relationships to Disclose
 
Erin Walicki
No Relationships to Disclose
 
Michael Postow
Consulting or Advisory Role - Bristol-Myers Squibb; Cancer Expert Now; Chugai Pharma; Eisai; Erasca, Inc; Intellisphere; Lyvgen Biopharma; Merck; MJH Associates; Nektar; Novartis; Pfizer; WebMD
Research Funding - Array BioPharma (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImaginAb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Jae Park
Stock and Other Ownership Interests - Curocell
Consulting or Advisory Role - Adaptive Biotechnologies; AffyImmune Therapeutics; Allogene Therapeutics; Amgen; Artiva; Autolus; Be Biopharma; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Caribou Biosciences; Galapagos UK; GC Cell; In8Bio; Intellia Therapeutics; Kite, a Gilead company; Kura Oncology; Minerva Biotechnologies; Novartis; Pfizer; Precision Biosciences; SERVIER; SOBI; Synthekine; Takeda
Research Funding - Autolus Therapeutics (Inst); Caribou Biosciences (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Takeda (Inst)
 
Charlotte Ariyan
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
Consulting or Advisory Role - Iovance Biotherapeutics; Merck
Speakers' Bureau - Bristol-Myers Squibb
 
Katherine Panageas
Stock and Other Ownership Interests - 23andMe; EyePoint Pharmaceuticals (I); Kyverna Therapeutics (I); Vincerx Pharma
Research Funding - AACR (Inst)
Travel, Accommodations, Expenses - AACR Project GENIE; The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Awards) in collaboration with the American Association for Cancer Research (AACR), Bristol Myers Squibb Foundation
 
Alexander Shoushtari
Consulting or Advisory Role - Erasca, Inc; Immunocore
Research Funding - Bristol-Myers Squibb (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Mural Oncology (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate